vs
AETHLON MEDICAL INC（AEMD）与Autonomix Medical, Inc.（AMIX）财务数据对比。点击上方公司名可切换其他公司
AETHLON MEDICAL INC自由现金流更多（$-2.0M vs $-3.0M）
AETHLON MEDICAL INC是一家临床阶段医疗科技企业，专注开发针对性治疗类医疗器械，核心产品血液净化器可从血液中去除有害病毒、肿瘤外泌体及其他病原体，业务聚焦传染病和肿瘤治疗赛道，主要市场覆盖北美地区。
Autonomix Medical是一家专注于心脏电生理领域的医疗科技企业，主要开发用于心律失常诊断与治疗的微创医疗设备，服务北美、欧洲地区的医疗机构与患者，致力于提升心律相关心脏疾病的诊疗效率与效果。
AEMD vs AMIX — 直观对比
营收规模更大
AEMD
是对方的Infinity倍
$0
自由现金流更多
AEMD
多$963.0K
$-3.0M
损益表 — Q3 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $60.0K | $0 |
| 净利润 | $-1.8M | $-3.3M |
| 毛利率 | — | — |
| 营业利润率 | -3026.4% | — |
| 净利率 | -2926.4% | — |
| 营收同比 | — | — |
| 净利润同比 | 49.4% | -20.2% |
| 每股收益（稀释后） | $-10.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEMDAMIX
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | $60.0K | $0 | ||
| Q3 24 | $95.1K | $0 | ||
| Q2 24 | — | $0 | ||
| Q4 23 | — | $0 |
净利润AEMDAMIX
| Q4 25 | — | $-3.3M | ||
| Q3 25 | — | $-7.5M | ||
| Q2 25 | — | $-3.3M | ||
| Q1 25 | — | $-3.2M | ||
| Q4 24 | $-1.8M | $-2.7M | ||
| Q3 24 | $-2.8M | $-2.8M | ||
| Q2 24 | — | $-2.7M | ||
| Q4 23 | — | $-3.1M |
营业利润率AEMDAMIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3026.4% | — | ||
| Q3 24 | -3050.2% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
净利率AEMDAMIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2926.4% | — | ||
| Q3 24 | -2950.2% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
每股收益（稀释后）AEMDAMIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-10.05 | — | ||
| Q3 24 | $-16.11 | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.8M | $9.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3M | $8.6M |
| 总资产 | $6.5M | $10.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AEMDAMIX
| Q4 25 | — | $9.9M | ||
| Q3 25 | — | $7.5M | ||
| Q2 25 | — | $8.6M | ||
| Q1 25 | — | $9.1M | ||
| Q4 24 | $4.8M | $11.8M | ||
| Q3 24 | $6.9M | $5.2M | ||
| Q2 24 | — | $6.8M | ||
| Q4 23 | — | — |
总债务AEMDAMIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | $1.5M |
股东权益AEMDAMIX
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $6.4M | ||
| Q2 25 | — | $7.0M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | $4.3M | $9.7M | ||
| Q3 24 | $6.0M | $3.0M | ||
| Q2 24 | — | $5.3M | ||
| Q4 23 | — | $-5.6M |
总资产AEMDAMIX
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $7.9M | ||
| Q2 25 | — | $9.0M | ||
| Q1 25 | — | $9.8M | ||
| Q4 24 | $6.5M | $12.0M | ||
| Q3 24 | $8.8M | $5.4M | ||
| Q2 24 | — | $7.1M | ||
| Q4 23 | — | $1.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $-3.0M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-3.0M |
| 自由现金流率自由现金流/营收 | -3357.0% | — |
| 资本支出强度资本支出/营收 | 3.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AEMDAMIX
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | $-3.8M | ||
| Q2 25 | — | $-2.6M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | $-2.0M | $-2.3M | ||
| Q3 24 | $-2.2M | $-1.6M | ||
| Q2 24 | — | $-1.9M | ||
| Q4 23 | — | — |
自由现金流AEMDAMIX
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-2.0M | $-2.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-1.9M | ||
| Q4 23 | — | — |
自由现金流率AEMDAMIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3357.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
资本支出强度AEMDAMIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
